智翔金泰首次公开发行股票募集资金总额347,283.84万元；扣除发行费用后，募集资金净额为329,140.14 万元。智翔金泰实际募资净额比原拟募集资金金额少68,859.86万元。智翔金泰于2023年6月15日披露的 招股说明书显示，该公司拟募集资金398,000.00万元，用于抗体产业化基地项目一期改扩建、抗体产业 化基地项目二期、抗体药物研发项目、补充流动资金。 智翔金泰首次公开发行股票的发行费用合计18,143.70万元(不含税)，其中，保荐承销费16,495.98万元。 中国经济网北京8月6日讯智翔金泰(688443.SH)今日收报33.60元，跌幅2.50%。目前该股处于破发状 态。 智翔金泰于2023年6月20日在上交所科创板上市，公开发行新股9,168.0000万股，发行价格为37.88元/ 股，保荐机构(主承销商)为海通证券股份有限公司(现名"国泰海通证券股份有限公司")，保荐代表人为 王永杰、刘丹。 ...

每经AI快讯，有投资者在投资者互动平台提问：GR1802注射液治疗特应性皮炎多久能读出数据？ 智翔金泰（688443.SH）8月1日在投资者互动平台表示，GR1802注射液中重度特应性皮炎适应症于2024 年8月完成III期临床试验入组，目前处于III期临床试验阶段。 （文章来源：每日经济新闻） ...

Group 1 - The core point of the article is that the company, Zhixiang Jintai, has received acceptance for its new drug application for GR2001 injection, which is currently in the review queue, but did not apply for priority review during the listing application process [2][3] - The GR2001 injection is recognized as a breakthrough therapy, indicating its potential significance in treatment [2] - The new drug application was officially accepted in May 2025, suggesting a timeline for potential market entry [2]

Core Viewpoint - The company has confirmed the receipt of a $20 million upfront payment related to the licensing and commercialization agreement for the GR1803 injection with Cullinan, and will recognize this revenue according to accounting policies [1] Group 1 - The company has received the $20 million upfront payment as part of the agreement with Cullinan [1] - The licensing and commercialization agreement for GR1803 injection has been signed and is in effect [1] - The company advises investors to refer to its announcements and periodic reports for detailed information [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购方案首次披露日 2024/10/16 回购方案实施期限 2024 年 10 月 15 日~2025 年 10 月 14 日 预计回购金额 2,000万元~4,000万元 回购价格上限 39.83元/股 □减少注册资本 √用于员工持股计划或股权激励 回购用途 □用于转换公司可转债 □为维护公司价值及股东权益 实际回购股数 796,100股 实际回购股数占总股本比例 0.2171% 实际回购金额 20,297,339.45元 实际回购价格区间 22.89元/股~29.43元/股 一、 回购审批情况和回购方案内容 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）于 2024 年 10 月 15 日召开第一届董事会第十六次会议，审议通过了《关于以集中竞价交易方式回购 股份的方案》，同意公司以集中竞价交易方式回购公司 A 股股份，回购的 A 股股 份拟用于员工持股计划或股权激励，回购资金金额不低于人民币 2,000 万元，不超 过人民币 4,000 万元，回购价格不 ...

证券日报网讯7月30日晚间，智翔金泰发布公告称，2025年7月30日，公司完成回购，已实际回购公司股 份796，100股，占公司总股本的0.2171%。 ...

每经AI快讯，智翔金泰（SH 688443，收盘价：33.41元）7月30日晚间发布公告称，2025年7月30日，公 司完成回购，已实际回购公司股份约80万股，占公司总股本的0.2171%，回购最高价格29.43元/股，回 购最低价格22.89元/股，回购均价约25.5元/股，使用资金总额约2030万元。 每经头条（nbdtoutiao）——装个"AI脑"售价飙十倍！马斯克已下场，阿里、美团等大厂前高管正涌 入，这个万亿级赛道火了 （记者 王晓波） 2024年1至12月份，智翔金泰的营业收入构成为：医药制造业占比99.92%，其他业务占比0.08%。 截至发稿，智翔金泰市值为123亿元。 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2025-030 二、 回购实施情况 （一）2024 年 11 月 19 日，公司首次实施回购股份，并于 2024 年 11 月 20 日 披露了首次回购股份情况，详见公司披露于上海证券交易所（www.sse.com.cn）及 指定信息披露媒体上的《关于首次回购股份的公告》（公告编号 2024-039）。 重庆智翔金泰生物制药股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/10/16 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2024 年 10 月 10 | 15 | 日~2025 | 年 | 14 日 | 月 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | 回购价格上限 | 39.83元/股 | | | | | | | 回购用途 | □ ...

格隆汇7月30日丨智翔金泰(688443.SH)公布，2025年7月30日，公司完成回购，已实际回购公司股份 79.61万股，占公司总股本的0.2171%，回购最高价格29.43元/股，回购最低价格22.89元/股，回购均价约 25.50元/股，使用资金总额2029.73万元（不含佣金、过户费等交易费用）。 ...

Group 1: Company Announcements - Zhixiang Jintai received approval for clinical trials of its drug, Sileweimi Monoclonal Antibody Injection, for passive immunity in children and adolescents exposed to suspected rabies virus [1] - Liyuan Technology's actual controller, Shen Wanzhong, received a criminal judgment for violating information disclosure laws, resulting in a one-year prison sentence with a one-and-a-half-year probation and a fine of 3.3 million yuan [1] - Shijia Photon reported a net profit of 217 million yuan for the first half of 2025, a year-on-year increase of 1712% [2] - Xinghua New Materials expects a net profit of 75 million to 85 million yuan for the first half of 2025, representing a year-on-year growth of 12.37% to 27.36% [3] - Greenland Holdings achieved a contract sales amount of 21.752 billion yuan in the second quarter, a year-on-year increase of 16.93% [4] Group 2: Shareholder Actions - Bluefeng Biochemical announced that a shareholder plans to reduce its stake by up to 2.61% [5] - Jiahe Meikang's shareholder intends to reduce its stake by up to 3% [5] - Lakaala reported that Lenovo Holdings reduced its stake by 535,960 shares, representing 0.68% of the total share capital [12] - Anji Food's controlling shareholder plans to reduce its stake by up to 2% [16] - Tongding Interconnect's shareholder plans to reduce its stake by up to 2.08% [20] Group 3: Strategic Partnerships and Investments - Yitian Intelligent signed distribution agreements with SMEG and Simico for a three-year period [6] - Daoshi Technology entered into a strategic cooperation agreement with Nengsida and Chipason to collaborate on materials for humanoid robot components [22]